|= Emerging. More than 5 years before clinical availability. (17.55%)|
|= Expected to be clinically available in 1 to 4 years. (42.72%)|
|= Clinically available now. (39.74%)|
|Percent of confirmed presenters indicating Clinical Use Status: 100.00%|
Authors: Malin Johansson (1), Shahid Ullah (2), Nikolai Stephanson (3), Gerd Ackehed (4)
Aerosol particles in exhaled breath containing organic substances are collected using a specific collector, called Breath Explore. After sample preparation the aerosol particles are analyzed by a LC - triple quadrupole mass spectrometer. Method was used for analysis of 16 drugs of abuse. The chromatography of morphine was randomly affected by an interference. Preliminary investigation suggests, polyglycols together with evaporation step, may be responsible for the interference. It seems that evaporation of sample extract is a critical step for morphine analysis. Further investigation with more conclusive results will be presented at the conference.
The chromatography of morphine is affected by an interference. The interference appears randomly in some sample and not in others.
•Sample preparation: Extraction from collector to acidified methanol solution, evaporation to dryness, reconstitution in methanol and ammonia
•Ion source type: H-ESI
•Instrument: Thermo LC-MS/MS Dionex Ultimate 3000 UHPLC-TSQ QUANTIVA
•Mobile phase A: 4 mmol/L Ammonium Formate in 0.05% ammonia in H2O
•Mobile phase B: 4 mmol/L Ammonium Formate with 0.05% ammonia in methanol
•Gradient: 5 minutes with 0.650 mL/min flow rate
•Column: Phenyl C18 2.1x100, 1.7 µm
•Column oven temperature: 65 ᵒC
•Injection volume: 2 µL
•Acquisition: Quantitative SRM
The LC was ruled out after several tests. The different steps of sample preparation, sample collector, extraction solvents, and evaporation were investigated.
The presence of polyglycols and the evaporation step during sample preparation are the most likely causes of the interference, however, the source of the interference is still under investigation.
References & Acknowledgements:
IP Royalty: no
|Planning to mention or discuss specific products or technology of the company(ies) listed above:||